{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:00:27Z","timestamp":1788102027866,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jgar.2017.03.018","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T22:45:56Z","timestamp":1500504356000},"page":"271-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014)"],"prefix":"10.1016","volume":"10","author":[{"given":"Leonard R.","family":"Duncan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2017.03.018_bib0005","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2010.10.031","article-title":"In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Karlowsky","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2017.03.018_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2011.05.012","article-title":"Update on the telavancin activity tested against European staphylococcal clinical isolates (2009\u20132010)","volume":"71","author":"Mendes","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2017.03.018_bib0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.diagmicrobio.2011.09.023","article-title":"Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007\u20132009)","volume":"72","author":"Mendes","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2017.03.018_bib0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diagmicrobio.2014.12.011","article-title":"Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method","volume":"81","author":"Mendes","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2017.03.018_bib0025","series-title":"VIBATIV","author":"Theravance Biopharma","year":"2016"},{"key":"10.1016\/j.jgar.2017.03.018_bib0030","series-title":"Summary Basis of Decision (SBD).","author":"Health Canada","year":"2017"},{"key":"10.1016\/j.jgar.2017.03.018_bib0035","series-title":"VIBATIV: summary of product characteristics","author":"European Medicines Agency","year":"2014"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2017.03.018_bib0040","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1093\/cid\/civ522","article-title":"Telavancin: the long and winding road from discovery to Food and Drug Administration approvals and future directions","volume":"61","author":"Wenzler","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.03.018_bib0045","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1345\/aph.1Q331","article-title":"Successful treatment of polymicrobial calcaneal osteomyelitis with telavancin, rifampin, and meropenem","volume":"46","author":"Brinkman","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0050","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1128\/AAC.00062-10","article-title":"Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model","volume":"54","author":"Crandon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0055","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.01101-08","article-title":"Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits","volume":"53","author":"Darouiche","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0060","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/jac\/dkq028","article-title":"Activity of telavancin against heterogeneous vancomycin-intermediate Staphylcoccus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia","volume":"65","author":"Hegde","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0065","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/jac\/dkr234","article-title":"Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure","volume":"55","author":"Joson","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0070","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/jac\/dks165","article-title":"Successful treatment of methicillin-resistant Staphylococcus epidermidis prosthetic joint infection with telavancin","volume":"67","author":"Kaushal","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0075","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkl222","article-title":"Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus","volume":"58","author":"Reyes","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0080","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/jac\/dkr329","article-title":"Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis","volume":"66","author":"Twilla","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0085","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1128\/AAC.00922-12","article-title":"Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus","volume":"56","author":"Xiong","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0090","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1753465816651594","article-title":"Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience","volume":"10","author":"Liapikou","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jgar.2017.03.018_bib0095","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0100","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.00301-10","article-title":"In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates","volume":"54","author":"Mendes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0105","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1128\/AAC.00011-12","article-title":"Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents","volume":"56","author":"Mendes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.diagmicrobio.2010.03.009","article-title":"Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results","volume":"67","author":"Putnam","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2017.03.018_bib0115","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2017.03.018_bib0120","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1128\/AAC.03172-14","article-title":"Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.03.018_bib0125","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-sixth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"10.1016\/j.jgar.2017.03.018_bib0130","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. January 2016. http:\/\/www.eucast.org\/clinical_breakpoints\/ [Accessed January 2016]."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T03:59:55Z","timestamp":1535601595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716517301248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":26,"alternative-id":["S2213716517301248"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2017.03.018","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2017.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}